Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, announced that it has received a Notice of Allowance (NOA) from the United States Patent and Trademark Office (USPTO) for a patent application pertaining to its EVM401 Series of molecules being developed as potential treatments for mental health disorders.

The USPTO issues a Notice of Allowance after making the determination that a patent should be granted from an application.

Entitled “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives,” the application will be the fourth Enveric patent application to be issued for Enveric’s EVM401 Series of molecules. Claims covered by this patent will further broaden Enveric’s pipeline by covering additional potential neuroplastogenic non-hallucinogenic molecules and strengthening its potential to target neuropsychiatric and addiction disorders for patients with few options.

“Enveric is pleased with this upcoming addition to its overall patent estate and the growing pipeline of potential EVM401 molecules. This expansion of Enveric intellectual property demonstrates the Company’s ability to develop next-generation, non-hallucinogenic neuroplastogens intended for potential treatment of neuropsychiatric conditions," said Joseph Tucker, Ph.D., Director and CEO of Enveric.